suramin has been researched along with Peritoneal Neoplasms in 3 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Peritoneal Neoplasms: Tumors or cancer of the PERITONEUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Suramin treatment inhibited in vivo growth in the REN intraperitoneal model shown grossly by necropsy of same day deaths comparing treatment and control animals." | 5.32 | Suramin inhibits the growth of malignant mesothelioma in vitro, and in vivo, in murine flank and intraperitoneal models. ( Cook, JW; Kaiser, LR; Singhal, S; Smythe, WR; Sterman, DH, 2003) |
| " Regular pharmacokinetic sampling of plasma and ascites fluid was carried out." | 2.69 | Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy. ( Baars, JP; Beijnen, JH; Dubbelman, R; Moolenaar, WH; Rodenhuis, S; Westermann, AM, 2000) |
| "Suramin treatment inhibited in vivo growth in the REN intraperitoneal model shown grossly by necropsy of same day deaths comparing treatment and control animals." | 1.32 | Suramin inhibits the growth of malignant mesothelioma in vitro, and in vivo, in murine flank and intraperitoneal models. ( Cook, JW; Kaiser, LR; Singhal, S; Smythe, WR; Sterman, DH, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cook, JW | 1 |
| Sterman, DH | 1 |
| Singhal, S | 1 |
| Smythe, WR | 1 |
| Kaiser, LR | 1 |
| Westermann, AM | 2 |
| Dubbelman, R | 2 |
| Moolenaar, WH | 2 |
| Beijnen, J | 1 |
| Rodenhuis, S | 2 |
| Baars, JP | 1 |
| Beijnen, JH | 1 |
1 trial available for suramin and Peritoneal Neoplasms
| Article | Year |
|---|---|
Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.
Topics: Adult; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Dru | 2000 |
2 other studies available for suramin and Peritoneal Neoplasms
| Article | Year |
|---|---|
Suramin inhibits the growth of malignant mesothelioma in vitro, and in vivo, in murine flank and intraperitoneal models.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; H | 2003 |
Successful intraperitoneal suramin treatment of peritoneal mesothelioma.
Topics: Adult; Antineoplastic Agents; Follow-Up Studies; Humans; Male; Mesothelioma; Peritoneal Neoplasms; S | 1997 |